Nycomed GmbH

Konstanz, Germany

Nycomed GmbH

Konstanz, Germany

Time filter

Source Type

Patent
Nycomed Gmbh | Date: 2013-04-10

A composition comprising: roflumilast having a purity of greater than or equal to 99% by weight, and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight.


Patent
Nycomed Gmbh | Date: 2013-01-18

Disclosed herein are novel methods of treating respiratory diseases, and in particular the treatment of asthmatic children.


Patent
Nycomed Gmbh | Date: 2012-04-02

Use of an adsorbent and a sealed package (e.g. an overwrap) to protect a pharmaceutical product in a solid state in the presence of a reducing sugar.


Patent
Nycomed GmbH | Date: 2012-10-10

Fixed combination, non-fixed combination or kit of parts comprising 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione, pioglitazone or a pharmaceutically acceptable salt of pioglitazone, and at least one pharmaceutically acceptable auxiliary.


Patent
Nycomed Gmbh | Date: 2012-02-01

The subject matter of this application is directed to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1.


Disclosed herein are salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4 inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical compositions.


Patent
NYCOMED GmbH | Date: 2012-11-29

An aqueous pharmaceutical composition which comprises ciclesonide, crystalline cellulose carmellose sodium and hydroxypropylmethylcellulose is provided.


An immediate release solid dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor, comprising a PDE 4 inhibitor that is N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (roflumilast) or a salt thereof, and one or more suitable pharmaceutical excipients; wherein said dosage form contains 500 g of the roflumilast or salt thereof.


Patent
Nycomed Gmbh | Date: 2012-07-12

The invention relates to novel processes for the preparation of high-purity roflumilast.


Patent
Nycomed Gmbh | Date: 2013-04-10

A method for the treatment of chronic obstructive pulmonary disease (COPD), including administering to a patient suffering from COPD, a therapeutically effective amount of roflumilast having a purity of greater than or equal to 99% by weight, and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight.

Loading Nycomed GmbH collaborators
Loading Nycomed GmbH collaborators